Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue and Product Sales Performance
AMGN logo

Amgen Revenues Rise 6% to $8.6 Billion as Volume Growth Offsets Pricing Pressures

AMGN10-QFiling Date: 5/1/2026
Amgen Inc.
Description

What this story covers

Amgen reported a resilient first quarter with 6% revenue growth, driven by strong volumes in products like Repatha. Despite pricing headwinds from the Inflation Reduction Act and biosimilar competition, the company maintains a robust $12 billion cash position.

Story snapshot

CompanyAmgen Inc.
TickerAMGN
VariantStandard detailed
Duration11:46
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000318154-26-000057
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in